Visceral obesity and inflammation markers in relation to serum prostate volume biomarkers among apparently healthy men

Alokail, Majed S.; Al-Daghri, Nasser M.; Al‐Attas, Omar S.; Alkharfy, Khalid M.; Sabico, Shaun; Ullrich, Axel

doi:10.1111/j.1365-2362.2011.02496.x

Cited by 5 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found a positive relationship between prostate volume and WC in Klinefelter subjects, confirming previous studies in other populations (12,13). Furthermore, subjects with WC R94 cm had significantly higher prostate volume with respect to those with WC !94 cm.…”

Section: Discussionsupporting

confidence: 80%

“…Of almost 26 000 male participants in the Health Professionals Follow-up Study, those with an obese waist circumference (WC) (O109 cm) were 38% more likely to undergo BPH surgery than those with a nonobese WC (!89 cm) (10), and data from the Prostate Cancer Prevention Trial (PCPT) indicated a 10% increased risk for total and severe BPH for every 5 cm increase in waist:hip ratio (11). Furthermore, a link has been demonstrated between insulin resistance and visceral adiposity with prostate volume markers among apparently healthy men and several reports have demonstrated a strong association between high insulin and leptin levels with BPH (12,13).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prostate volume and growth during testosterone replacement therapy is related to visceral obesity in Klinefelter syndrome

Selice

Caretta

Mambro

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Klinefelter syndrome (KS) is a chromosomal alteration characterized by increased risk of metabolic syndrome, mainly caused by visceral obesity. In the last years, obesity has been studied as a potential risk factor for prostate disease and recently a link has been demonstrated between visceral adiposity with prostate volume. The aim of this study was to analyze the relationship between obesity and prostate volume and growth during testosterone therapy in KS subjects. Design and methods: We evaluated reproductive hormones, metabolic parameters, anthropometric measures, PSA, and prostate volume in 121 naïve non-mosaic KS patients and 60 age-matched healthy male controls. Fifty-six KS hypogonadic subjects were treated with testosterone-gel 2% and reevaluated after 18 months of treatment. Results: Prostate volume in KS was positively related to waist circumference (WC). The KS group with WC R94 cm had significantly higher prostate volume, BMI, insulin plasma levels, homeostasis model assessment index, total cholesterol, triglycerides, and glycemia with respect to the KS group with WC !94 cm. After testosterone replacement therapy, only hypogonadic KS men with WC R94 cm had a statistically significant increase in prostate volume. Furthermore, in untreated KS subjects, prostate volume showed a statistically significant increase after 18 months of follow-up only in subjects with WC R94 cm. Conclusions: This study showed that visceral obesity, insulin resistance, and lipid and glucose metabolism alterations are associated with prostate volume and growth during testosterone replacement therapy in KS, independently from androgen or estrogen levels. These latter findings might provide the basis for a better management and follow-up of KS subjects.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Introductionmentioning

confidence: 99%

Prostate volume and growth during testosterone replacement therapy is related to visceral obesity in Klinefelter syndrome

Selice

Caretta

Mambro

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Although most investigators have reported a positive association between IGF1 level (or IGF1/IGFBP3 ratio) and cancer risk, others have reported significant inverse associations, including in prostate cancer (Alokail et al 2011) and melanoma (Panasiti et al 2011, Park et al 2011b, for example. In addition, whereas large increases in IGFBP1 were reported to significantly raise the risk of overall cancer mortality in patients (Kaplan et al 2012), global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model (Gray et al 2011).…”

Section: Ilp Molecules and Cancer Riskmentioning

confidence: 99%

Insulin resistance and cancer: the role of insulin and IGFs

Djiogue¹,

Kamdje²,

Vecchio³

et al. 2012

Endocrine-Related Cancer

232

188

View full text Add to dashboard Cite

Insulin, IGF1, and IGF2 are the most studied insulin-like peptides (ILPs). These are evolutionary conserved factors well known as key regulators of energy metabolism and growth, with crucial roles in insulin resistance-related metabolic disorders such as obesity, diseases like type 2 diabetes mellitus, as well as associated immune deregulations. A growing body of evidence suggests that insulin and IGF1 receptors mediate their effects on regulating cell proliferation, differentiation, apoptosis, glucose transport, and energy metabolism by signaling downstream through insulin receptor substrate molecules and thus play a pivotal role in cell fate determination. Despite the emerging evidence from epidemiological studies on the possible relationship between insulin resistance and cancer, our understanding on the cellular and molecular mechanisms that might account for this relationship remains incompletely understood. The involvement of IGFs in carcinogenesis is attributed to their role in linking high energy intake, increased cell proliferation, and suppression of apoptosis to cancer risks, which has been proposed as the key mechanism bridging insulin resistance and cancer. The present review summarizes and discusses evidence highlighting recent advances in our understanding on the role of ILPs as the link between insulin resistance and cancer and between immune deregulation and cancer in obesity, as well as those areas where there remains a paucity of data. It is anticipated that issues discussed in this paper will also recover new therapeutic targets that can assist in diagnostic screening and novel approaches to controlling tumor development.

show abstract

“…Furthermore, a study of 219 men investigated visceral obesity and inflammatory markers in relation to circulating total prostate-specific antigen (PSA) levels, a surrogate for prostate volume [15]. They found an inverse association of total PSA with serum adiponectin levels, an endogenous insulin-sensitising adipocytokine with anti-inflammatory properties, and a positive association with waist-hip ratio [15]. It is therefore plausible that inflammation is the connection between obesity and BPH.…”

Section: Introductionmentioning

confidence: 99%

“…Higher BMI has also been significantly related to increased levels of seminal interleukin-8 which is known to be a reliable surrogate marker of prostate inflammatory diseases [8]. Furthermore, a study of 219 men investigated visceral obesity and inflammatory markers in relation to circulating total prostate-specific antigen (PSA) levels, a surrogate for prostate volume [15]. They found an inverse association of total PSA with serum adiponectin levels, an endogenous insulin-sensitising adipocytokine with anti-inflammatory properties, and a positive association with waist-hip ratio [15].…”

Section: Introductionmentioning

confidence: 99%

Body Mass Index Predicts Failure of Surgical Management in Benign Prostatic Hyperplasia

Willder

Walker²,

Halbert³

et al. 2012

Urol Int

View full text Add to dashboard Cite

Introduction: Inflammation is postulated to link obesity and benign prostatic hyperplasia (BPH). The role of inflammation and the prognostic significance of body mass index (BMI) was investigated in BPH patients. Subjects and Methods: Consecutive patients with histological BPH were identified from 1996 to 2005. Systemic inflammation was assessed by modified Glasgow Prognostic Score (mGPS) and local inflammation by Klintrup-Makinen criteria. Results: In 392 patients, BMI was associated with cardiovascular disease (p = 0.033), type 2 diabetes mellitus (p = 4.45 × 10^-8), aspirin usage (p = 0.018) and failure of surgical treatment (p = 0.001). mGPS and Klintrup-Makinen scores were not associated with clinical variables or outcome measures. On multivariate analysis BMI was an independent predictor of time to failure of surgical management of BPH, HR 1.56 (95% CI 1.11-2.19), p = 0.010. Conclusions: The mGPS and Klintrup-Makinen scores were not associated with BMI in BPH patients. High BMI is associated with failure of surgical management of BPH. Preoperative weight loss should be strongly encouraged in these patients.

show abstract

Visceral obesity and inflammation markers in relation to serum prostate volume biomarkers among apparently healthy men

Cited by 5 publications

References 34 publications

Prostate volume and growth during testosterone replacement therapy is related to visceral obesity in Klinefelter syndrome

Prostate volume and growth during testosterone replacement therapy is related to visceral obesity in Klinefelter syndrome

Insulin resistance and cancer: the role of insulin and IGFs

Body Mass Index Predicts Failure of Surgical Management in Benign Prostatic Hyperplasia

Contact Info

Product

Resources

About